CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
LY3039478 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02518113
NCT02518113Phase 2Completed
CompareCT.gov

A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients

Eli Lilly and Company·interventional·Posted Aug 7, 2015·Updated Sep 11, 2019

In Brief

A Phase 2 clinical trial evaluating LY3039478, Dexamethasone, and 1 other intervention for T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma. Completed, enrolled 36 participants across 22 sites in 5 countries.

Detailed Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
CountriesFrance, Germany, Israel, Italy, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 7, 2015
Enrollment StartOct 1, 2015
Primary CompletionJan 15, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.9 years ago

Interventions

LY3039478drug

Administered orally

Dexamethasonedrug

Administered orally

Placebodrug

Administered orally